In vivo PD evaluations

In vivo pharmacodynamics (PD) evaluations involve assessing the biological effects of a drug within a living organism. These evaluations are designed to determine the drug's efficacy, mechanism of action, therapeutic index, and potential side effects. Typically conducted using animal models, in vivo PD evaluations help researchers understand how a drug interacts with physiological systems, its relationship to dosage, and the overall impact on health outcomes. Such studies are essential for drug development, aiding in the transition from preclinical research to clinical trials.

Oncology / Immune Oncology

Allograft model
Xenograft model
Spontaneous tumor model

Metabolism Disease

NASH model
Hyperuricemia
Hepatic/Pulmonary fibrosis
Diabetes model

Neurological System Disease

AD
PD
Pain

Autoimmune Disease

Asthma
RA/CIA
Psoriasis
IBD
EAE
AD

Oncology Efficacy Evaluation Platform

New generation therapies, such as anti-tumor targeted drugs, immunotherapy, and gene therapy, have achieved significant success in the treatment of malignant tumors and have great potential for clinical application. These therapies are the key focus of future anti-tumor research. Suitable animal models can help scientists replicate physiological and pathological conditions similar to human tumor development, enabling more accurate candidate drug screening and efficacy evaluation, and providing a competitive edge in the increasingly competitive field of new drug development.

GenoBioTX has established a comprehensive and professional tumor efficacy evaluation platform with hundreds of tumor efficacy evaluation models. This platform provides clients with preclinical services, including candidate drug screening, pharmacological and efficacy evaluation, pharmacokinetics evaluation, and early toxicology evaluation.

Syngeneic Models

Mouse Cells

Tumor-bearing Pleural Effusion Model Construction and Efficacy Evaluation

Subcutaneous Colorectal Cancer Xenograft Model Construction and Efficacy Evaluation

Genetically Modified Spontaneous Tumor Models

The genetically modified spontaneous tumor models are constructed by altering the genes of mice to develop spontaneous tumors. Typically, this involves gene modifications targeting oncogenes or tumor suppressor genes, where disrupting or regulating their expression can induce tumor formation. GenoBioTX has independently developed a variety of spontaneous tumor mouse models to support clinical drug development.

Stk11/EGFP/Kras-LsL-G12D Lung Spontaneous Tumor Models

Syngeneic Tumor Models with Target Humanized Mice

Many cancer drug targets are found in the immune system or tumor microenvironment rather than on the tumor itself. Wild-type mice lack humanized targets, making them unsuitable for evaluating these drugs. To address this, GenoBioTX has developed proprietary humanized mouse models, including immune checkpoint and cytokine/receptor humanized mice, ideal for assessing the efficacy and safety of antibody-based therapies.

900+ Therapeutic Humanized Mouse Models

Case Studies of Therapeutic Humanized Mouse Models

Anti-tumor Efficacy Study based on hCD3EDG Mice

Anti-tumor Efficacy Evaluation based on hPD1/hCTLA4 Humanized Mouse Models

Xenograft Tumor Mouse Model

200+ CDX Cell Lines

CDX Model Case Study

Nearly 2,000 PDX Model Resources

Case Studies of PDX Models

Immune-reconstituted Xenograft Tumor Models

The NMG severely immunodeficient mice and their derivatives, independently developed by GenoBioTX, can efficiently engraft HU-HSc and HU-PBMC, enabling the reconstruction of a human immune system in mice. These humanized immune system mouse models better simulate human immune characteristics and serve as essential tools for studying human immune function, infectious diseases, diabetes, tumor immunology, and stem cell biology.